Therapeutic area intelligence for Hormone Replacement with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 0
Companies: 1

Companies

Sandoz →

Assets

FDA →

Vasopressin →

Recent signals(5)

RegulatoryAugust 3, 2026

FDA Grants Approval for Vasopressin Application ANDA212068 by Sandoz

The FDA has granted approval for Sandoz's original application for Vasopressin under ANDA212068.

RegulatoryAugust 3, 2026

FDA Approval Process Update for Vasopressin by Sandoz

The FDA has accepted the application ANDA212069 for Vasopressin submitted by Sandoz, with a standard review priority.

RegulatoryJuly 22, 2026

FDA Accepts ANDA for Vasopressin in Dextrose 5% by Dr. Reddy's

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Vasopressin in Dextrose 5% submitted by Dr.

CompetitiveJuly 13, 2026

Sandoz Receives FDA Approval for Vasopressin ANDA212069

Sandoz has received an Abbreviated New Drug Application (ANDA) approval for Vasopressin.

StrategyJuly 13, 2026

Sandoz Receives FDA Approval for Vasopressin ANDA212068

Sandoz's ANDA212068 for Vasopressin has received an Abbreviated Approval from the FDA.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.